Reuters logo
BRIEF-Aimmune Therapeutics expects artemis to enroll 120-160 patients in Europe
2016年11月28日 / 下午1点17分 / 10 个月前

BRIEF-Aimmune Therapeutics expects artemis to enroll 120-160 patients in Europe

Nov 28 (Reuters) - Aimmune Therapeutics Inc:

* Aimmune Therapeutics completes global enrollment of phase 3 palisade trial of ar101 for the treatment of peanut allergy

* Says expects Artemis to enroll between 120 and 160 patients at multiple sites in Europe, beginning in mid-2017

* Aimmune - continues to expect topline data from palisade in q4 of 2017, followed by regulatory submissions for marketing approval of ar101 in 2018 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below